Cinnamaldehyde attenuates diabetic cardiomyopathy by ameliorating energy metabolism disturbance and activating autophagy.

IF 2.6 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Ming-Qiao Hu, Ke-Zhao Wei, Shi-Yu Wu, Xu Zhang, Xiao-Ting Zhang, Xu Xu, Xu-Hua Shen, Jian-Ping Gao
{"title":"Cinnamaldehyde attenuates diabetic cardiomyopathy by ameliorating energy metabolism disturbance and activating autophagy.","authors":"Ming-Qiao Hu, Ke-Zhao Wei, Shi-Yu Wu, Xu Zhang, Xiao-Ting Zhang, Xu Xu, Xu-Hua Shen, Jian-Ping Gao","doi":"10.1097/FJC.0000000000001694","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic Cardiomyopathy (DCM) is a diabetes mellitus-induced pathophysiological condition that can lead to heart failure. Cinnamaldehyde (CA), a bioactive phytochemical derived from the bark of Cinnamon, exhibits cardioprotective properties against heart injury in metabolic syndrome. This study aims to explore the role of CA on DCM and its cardioprotective mechanisms. Diabetic rats were established by injection of streptozotocin (STZ, 60∼85 mg/kg). Subsequently, CA (50 mg/kg) was administered via gavage daily for 28-day duration. Following this treatment, abnormalities levels of fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and LDL-C to HDL-C ratio were ameliorated. Additionally, CA inhibited cardiac histopathological alterations and hypertrophy, reduced brain natriuretic peptide (BNP) level, shortened S-T and P-R intervals on electrocardiogram, decreased tissue malondialdehyde content, and enhanced myocardial energy metabolism, including Creatine (Cr), adenosine triphosphate (ATP), adenosine monophosphate (AMP) and total adenine nucleotides (TAN). Furthermore, CA improved oxidative stress, improved myocardial Ca2+-Mg2+-ATPase activity and downregulated the mRNA expression of AMP protein activation kinase α2 (AMPK-α2), receptor γ coactivator-1 alpha (PGC-1α) and peroxisome proliferator-activated receptor α (PPARα), while also ameliorating protein expressions, including ratio of phosphorylated mammalian target of rapamycin to mechanistic target of rapamycin (p-mTOR/mTOR), level of SQSTM1/p62, and ratio of microtubule-associated protein 1 light chain 3 beta to microtubule-associated protein 1 light chain 3 alpha (LC3Ⅱ/ LC3Ⅰ). In conclusion, these findings indicate that CA can alleviate DCM by modulating AMPK-α2/PPAR-α/PGC-1α signaling pathway to restore energy metabolism and activating autophagy through mTOR signaling pathway.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001694","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetic Cardiomyopathy (DCM) is a diabetes mellitus-induced pathophysiological condition that can lead to heart failure. Cinnamaldehyde (CA), a bioactive phytochemical derived from the bark of Cinnamon, exhibits cardioprotective properties against heart injury in metabolic syndrome. This study aims to explore the role of CA on DCM and its cardioprotective mechanisms. Diabetic rats were established by injection of streptozotocin (STZ, 60∼85 mg/kg). Subsequently, CA (50 mg/kg) was administered via gavage daily for 28-day duration. Following this treatment, abnormalities levels of fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and LDL-C to HDL-C ratio were ameliorated. Additionally, CA inhibited cardiac histopathological alterations and hypertrophy, reduced brain natriuretic peptide (BNP) level, shortened S-T and P-R intervals on electrocardiogram, decreased tissue malondialdehyde content, and enhanced myocardial energy metabolism, including Creatine (Cr), adenosine triphosphate (ATP), adenosine monophosphate (AMP) and total adenine nucleotides (TAN). Furthermore, CA improved oxidative stress, improved myocardial Ca2+-Mg2+-ATPase activity and downregulated the mRNA expression of AMP protein activation kinase α2 (AMPK-α2), receptor γ coactivator-1 alpha (PGC-1α) and peroxisome proliferator-activated receptor α (PPARα), while also ameliorating protein expressions, including ratio of phosphorylated mammalian target of rapamycin to mechanistic target of rapamycin (p-mTOR/mTOR), level of SQSTM1/p62, and ratio of microtubule-associated protein 1 light chain 3 beta to microtubule-associated protein 1 light chain 3 alpha (LC3Ⅱ/ LC3Ⅰ). In conclusion, these findings indicate that CA can alleviate DCM by modulating AMPK-α2/PPAR-α/PGC-1α signaling pathway to restore energy metabolism and activating autophagy through mTOR signaling pathway.

糖尿病心肌病(DCM)是一种由糖尿病引起的病理生理状况,可导致心力衰竭。肉桂醛(Cinnamaldehyde,CA)是从肉桂树皮中提取的一种具有生物活性的植物化学物质,对代谢综合征的心脏损伤具有保护作用。本研究旨在探讨 CA 对 DCM 的作用及其心脏保护机制。通过注射链脲佐菌素(STZ,60∼85 mg/kg)建立糖尿病大鼠。随后,每天灌胃给予 CA(50 毫克/千克),持续 28 天。治疗后,空腹血糖(FBG)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值的异常水平得到改善。此外,CA 还能抑制心脏组织病理学改变和肥大,降低脑钠肽 (BNP) 水平,缩短心电图的 S-T 和 P-R 间期,降低组织丙二醛含量,增强心肌能量代谢,包括肌酸 (Cr)、三磷酸腺苷 (ATP)、单磷酸腺苷 (AMP) 和总腺嘌呤核苷酸 (TAN)。此外,CA 还能改善氧化应激,提高心肌 Ca2+-Mg2+-ATPase 活性,并下调 AMPK 蛋白激活激酶 α2 (AMPK-α2)、受体 γ 辅激活因子-1 α (PGC-1α) 和过氧化物酶体增殖激活受体 α (PPARα) 的 mRNA 表达、同时还能改善蛋白质表达,包括雷帕霉素磷酸化哺乳动物靶标与雷帕霉素机制靶标(p-mTOR/mTOR)的比率、SQSTM1/p62 的水平以及微管相关蛋白 1 轻链 3 beta 与微管相关蛋白 1 轻链 3 alpha 的比率(LC3Ⅱ/ LC3Ⅰ)。总之,这些研究结果表明,CA可通过调节AMPK-α2/PPAR-α/PGC-1α信号通路恢复能量代谢,并通过mTOR信号通路激活自噬,从而缓解DCM。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.10
自引率
3.30%
发文量
367
审稿时长
1 months
期刊介绍: Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias. Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信